Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

SGS-742 Novartis.

Roger Bullock1

  • 1The Kingshill Research Centre, Victoria Hospital, Swindon, UK. roger.bullock@kingshill-research.org

Current Opinion in Investigational Drugs (London, England : 2000)
|January 29, 2005
PubMed
Summary
This summary is machine-generated.

SGS-742, a GABA(B) antagonist, is being investigated for Alzheimer's disease (AD) and mild cognitive impairment. A Phase II trial began in 2004 to assess its potential in AD patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

REIMAGINE: A central nervous system basket trial showing safety and efficacy of vafidemstat on aggression in different psychiatric disorders.

Psychiatry and clinical neurosciences·2025
Same author

Potential Virus Involvement in Alzheimer's Disease: Results from a Phase IIa Trial Evaluating Apovir, an Antiviral Drug Combination.

Journal of Alzheimer's disease reports·2021
Same author

Pharmacological treatment of hypertension in people without prior cerebrovascular disease for the prevention of cognitive impairment and dementia.

The Cochrane database of systematic reviews·2021
Same author

Use of Flutemetamol F 18-Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment.

JAMA neurology·2018
Same author

Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease.

The New England journal of medicine·2018
Same author

Statins for the prevention of dementia.

The Cochrane database of systematic reviews·2016

Area of Science:

  • Neuroscience
  • Pharmacology
  • Clinical Trials

Background:

  • Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
  • Mild cognitive impairment (MCI) is a potential precursor to AD.
  • GABA(B) receptor antagonists are being explored for cognitive enhancement.

Purpose of the Study:

  • To evaluate the safety and efficacy of SGS-742 in patients with mild-to-moderate Alzheimer's disease.
  • To investigate the therapeutic potential of GABA(B) antagonism in cognitive disorders.

Main Methods:

  • Enrollment in a Phase II clinical trial for SGS-742 commenced in May 2004.
  • The study focuses on patients diagnosed with mild-to-moderate Alzheimer's disease.

Main Results:

Related Experiment Videos

  • Data on the main results are not yet available as the trial has recently begun enrollment.

Conclusions:

  • SGS-742 represents a potential novel therapeutic agent for Alzheimer's disease and MCI.
  • Further clinical investigation is warranted to determine the drug's efficacy and safety profile.